
    
      This is a single-institution, non-randomized phase 1/2 study in patients with
      locally-advanced or metastatic NSCLC in remission after receiving standard systemic
      chemotherapy of four cycles of combination chemotherapy consisting of four cycles of
      cisplatin combined with vinorelbine.
    
  